Poly(ADP-Ribose) Polymerase 1 Promotes Inflammation and Fibrosis in a Mouse Model of Chronic Pancreatitis

被引:11
作者
El-Hamoly, Tarek [1 ,2 ]
Hajnady, Zoltan [1 ,3 ]
Nagy-Penzes, Mate [1 ,3 ]
Bakondi, Edina [1 ]
Regdon, Zsolt [1 ,3 ]
Demeny, Mate A. [4 ]
Kovacs, Katalin [1 ,4 ]
Hegedus, Csaba [1 ]
Abd El-Rahman, Sahar S. [5 ]
Szabo, Eva [6 ]
Maleth, Jozsef [7 ,8 ,9 ]
Hegyi, Peter [10 ,11 ]
Virag, Laszlo [1 ,4 ]
机构
[1] Univ Debrecen, Dept Med Chem, Fac Med, H-4032 Debrecen, Hungary
[2] Atom Energy Author, Drug Radiat Res Dept, Natl Ctr Radiat Res & Technol, Cairo 11787, Egypt
[3] Univ Debrecen, Doctoral Sch Mol Med, H-4032 Debrecen, Hungary
[4] MTA DE Cell Biol & Signaling Res Grp, H-4032 Debrecen, Hungary
[5] Cairo Univ, Dept Pathol, Fac Vet Med, Giza 12211, Egypt
[6] Univ Debrecen, Dept Dermatol, Fac Med, H-4032 Debrecen, Hungary
[7] Univ Szeged, Dept Med 1, H-6720 Szeged, Hungary
[8] HAS USZ Momentum Epithel Cell Signalling & Secret, H-6720 Szeged, Hungary
[9] Univ Szeged, Dept Publ Hlth, H-6720 Szeged, Hungary
[10] Univ Pecs, Med Sch, Inst Translat Med, Janos Szentagothai Res Ctr, H-7624 Pecs, Hungary
[11] Univ Szeged, Hungarian Acad Sci, Momentum Gastroenterol Multidisciplinary Res Grp, H-6720 Szeged, Hungary
关键词
chronic pancreatitis; inflammation; fibrosis; cell death; poly(ADP-ribose) polymerase 1;
D O I
10.3390/ijms22073593
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chronic pancreatitis (CP) is an inflammatory disease of the pancreas characterized by ductal obstructions, tissue fibrosis, atrophy and exocrine and endocrine pancreatic insufficiency. However, our understanding is very limited concerning the disease's progression from a single acute inflammation, via recurrent acute pancreatitis (AP) and early CP, to the late stage CP. Poly(ADP-ribose) polymerase 1 (PARP1) is a DNA damage sensor enzyme activated mostly by oxidative DNA damage. As a co-activator of inflammatory transcription factors, PARP1 is a central mediator of the inflammatory response and it has also been implicated in acute pancreatitis. Here, we set out to investigate whether PARP1 contributed to the pathogenesis of CP. We found that the clinically used PARP inhibitor olaparib (OLA) had protective effects in a murine model of CP induced by multiple cerulein injections. OLA reduced pancreas atrophy and expression of the inflammatory mediators TNF alpha and interleukin-6 (IL-6), both in the pancreas and in the lungs. Moreover, there was significantly less fibrosis (Masson's trichrome staining) in the pancreatic sections of OLA-treated mice compared to the cerulein-only group. mRNA expression of the fibrosis markers TGF beta, smooth muscle actin (SMA), and collagen-1 were markedly reduced by OLA. CP was also induced in PARP1 knockout (KO) mice and their wild-type (WT) counterparts. Inflammation and fibrosis markers showed lower expression in the KO compared to the WT mice. Moreover, reduced granulocyte infiltration (tissue myeloperoxidase activity) and a lower elevation of serum amylase and lipase activity could also be detected in the KO mice. Furthermore, primary acinar cells isolated from KO mice were also protected from cerulein-induced toxicity compared to WT cells. In summary, our data suggest that PARP inhibitors may be promising candidates for repurposing to treat not only acute but chronic pancreatitis as well.
引用
收藏
页数:15
相关论文
共 39 条
  • [1] Accelerating the Drug Delivery Pipeline for Acute and Chronic Pancreatitis: Summary of the Working Group on Drug Development and Trials in Acute Pancreatitis at the National Institute of Diabetes and Digestive and Kidney Diseases Workshop
    Abu-El-Haija, Maisam
    Gukovskaya, Anna S.
    Andersen, Dana K.
    Gardner, Timothy B.
    Hegyi, Peter
    Pandol, Stephen J.
    Papachristou, Georgios I.
    Saluja, Ashok K.
    Singh, Vikesh K.
    Uc, Aliye
    Wu, Bechien U.
    [J]. PANCREAS, 2018, 47 (10) : 1185 - 1192
  • [2] Modulation of transcription by PARP-1:: Consequences in carcinogenesis and inflammation
    Aguilar-Quesada, R.
    Munoz-Gamez, J. A.
    Martin-Oliva, D.
    Peralta-Leal, A.
    Quiles-Perez, R.
    Rodriguez-Vargas, J. M.
    de Almodovar, M. Ruiz
    Conde, C.
    Ruiz-Extremera, A.
    Oliver, F. J.
    [J]. CURRENT MEDICINAL CHEMISTRY, 2007, 14 (11) : 1179 - 1187
  • [3] EFFECTS OF THE POLY(ADP-RIBOSE) POLYMERASE INHIBITOR OLAPARIB IN CERULEIN-INDUCED PANCREATITIS
    Ahmad, Akbar
    De Mello, Aline Haas
    Szczesny, Bartosz
    Toro, Gabor
    Marcatti, Michela
    Druzhyna, Nadiya
    Liaudet, Lucas
    Tarantini, Stefano
    Salomao, Reinaldo
    Soriano, Francisco Garcia
    Szabo, Csaba
    [J]. SHOCK, 2020, 53 (05): : 653 - 665
  • [4] Pancreatic stellate cells: a starring role in normal and diseased pancreas
    Apte, Minoti V.
    Pirola, Romano C.
    Wilson, Jeremy S.
    [J]. FRONTIERS IN PHYSIOLOGY, 2012, 3
  • [5] Spilanthol Inhibits Inflammatory Transcription Factors and iNOS Expression in Macrophages and Exerts Anti-inflammatory Effects in Dermatitis and Pancreatitis
    Bakondi, Edina
    Singh, Salam Bhopen
    Hajnady, Zoltan
    Nagy-Penzes, Mate
    Regdon, Zsolt
    Kovacs, Katalin
    Hegedus, Csaba
    Madacsy, Tamara
    Maleth, Jozsef
    Hegyi, Peter
    Demeny, Mate A.
    Nagy, Tibor
    Keki, Sandor
    Szabo, Eva
    Virag, Laszlo
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (17)
  • [6] Ductal Mucus Obstruction and Reduced Fluid Secretion Are Early Defects in Chronic Pancreatitis
    Balazs, Anita
    Balla, Zsolt
    Kui, Balazs
    Maleth, Jozsef
    Rakonczay, Zoltan, Jr.
    Duerr, Julia
    Zhou-Suckow, Zhe
    Schatterny, Jolanthe
    Sendler, Matthias
    Mayere, Julia
    Kuhn, Jens -P.
    Tiszlavicz, Laszlci
    Mall, Marcus A.
    Hegyi, Peter
    [J]. FRONTIERS IN PHYSIOLOGY, 2018, 9
  • [7] Cystic fibrosis-style changes in the early phase of pancreatitis
    Balazs, Anita
    Hegyi, Peter
    [J]. CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2015, 39 : S12 - S17
  • [8] Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases
    Berger, Nathan A.
    Besson, Valerie C.
    Boulares, A. Hamid
    Burkle, Alexander
    Chiarugi, Alberto
    Clark, Robert S.
    Curtin, Nicola J.
    Cuzzocrea, Salvatore
    Dawson, Ted M.
    Dawson, Valina L.
    Hasko, Gyorgy
    Liaudet, Lucas
    Moroni, Flavio
    Pacher, Pal
    Radermacher, Peter
    Salzman, Andrew L.
    Snyder, Solomon H.
    Soriano, Francisco Garcia
    Strosznajder, Robert P.
    Sumegi, Balazs
    Swanson, Raymond A.
    Szabo, Csaba
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2018, 175 (02) : 192 - 222
  • [9] Interactions between the Endocrine and Exocrine Pancreas and Their Clinical Relevance
    Czako, Laszlo
    Hegyi, Peter
    Rakonczay, Zoltan, Jr.
    Wittmann, Tibor
    Otsuki, Makoto
    [J]. PANCREATOLOGY, 2009, 9 (04) : 351 - 359
  • [10] Effects of PARP-1 Deficiency and Histamine H4 Receptor Inhibition in an Inflammatory Model of Lung Fibrosis in Mice
    Durante, Mariaconcetta
    Sgambellone, Silvia
    Lanzi, Cecilia
    Nardini, Patrizia
    Pini, Alessandro
    Moroni, Flavio
    Masini, Emanuela
    Lucarini, Laura
    [J]. FRONTIERS IN PHARMACOLOGY, 2019, 10